david g anderson - Neurology

Author Information

David G. Anderson is a distinguished researcher affiliated with The University of the Witwatersrand Donald Gordon Medical Centre, specializing in Neurology, located in Johannesburg, South Africa. Additionally, he is associated with the Division of Human Genetics at the National Health Laboratory Service and the School of Pathology within the Faculty of Health Sciences at The University of the Witwatersrand. His work primarily emphasizes neurological disorders, contributing significantly to the understanding of conditions such as Huntington's Disease and Parkinson's Disease.

Research Contributions

David G. Anderson's research portfolio is rich with studies focusing on the neurocognitive and neuropsychological aspects of various neurological disorders. Notably, his work has explored the distinctions between Huntington's Disease and Huntington Disease-Like 2, delving into their neuropsychological profiles and phenotypic spectrums. His studies also extend to functional neurological disorders and the genetic screening of Parkinson's Disease, emphasizing the importance of genetic factors in disease manifestation and progression. His research has made substantial contributions to the field, offering insights into diagnostic and therapeutic approaches for these complex conditions.

Aliases

David G. Anderson is also known by the aliases David Anderson and David G Anderson. These variations are used interchangeably in academic and professional circles.

Publication and Citation Metrics

Metric	Value
Total Citation Count	286
H-index	10
Total Number of Papers	25

Publications:

Assessing Parkinson's disease severity using speech analysis in non-native speakers

DOI: 10.1016/j.csl.2019.101047

Year: 2020

A comparison between the neurocognitive profile of Huntington Disease-Like 2 and Huntington Disease: Exploring the presence of double dissociations

DOI: 10.1080/23279095.2020.1734810

Year: 2020

The neuropsychological deficits and dissociations in Huntington Disease-Like 2: A series of case-control studies

DOI: 10.1016/j.neuropsychologia.2019.107238

Year: 2020

Single case-control design for the study of the neuropsychological deficits and dissociations in Huntington’s disease-like 2

DOI: 10.1016/j.mex.2020.100782

Year: 2020

Outcome measurement in functional neurological disorder: a systematic review and recommendations

DOI: 10.1136/jnnp-2019-322180

Year: 2020

A detailed description of the phenotypic spectrum of North Sea Progressive Myoclonus Epilepsy in a large cohort of seventeen patients.

DOI: 10.1016/j.parkreldis.2020.02.005

Year: 2020

Screening of the glucocerebrosidase (GBA) gene in South Africans of African ancestry with Parkinson's disease

DOI: 10.1016/j.neurobiolaging.2019.12.011

Year: 2020

The Neuropsychiatry of Huntington Disease-Like 2: A Comparison with Huntington's Disease.

DOI: 10.3233/JHD-200422

Year: 2020

Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes

DOI: 10.1002/mdc3.12742

Year: 2019

Emerging differences between Huntington's disease-like 2 and Huntington's disease: A comparison using MRI brain volumetry

DOI: 10.1016/j.nicl.2019.101666

Year: 2019

What Causes PPMS?

What Are Dopaminergic Drugs?

What Role Do Biomarkers Play?

What is Dystonia?

What are Neurological Deficits?

How Does CYP2D6 Affect Neurological Medications?

What is Myelin?

What are the Risks Involved?

How is Parkinson's Disease Diagnosed?

What is Early Intervention in Neurology?

Partnered Content Networks

Relevant Topics